• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

More Research Is Needed on Lifestyle Behaviors That Influence Progression of Parkinson's Disease
This article highlights some of these challenges in the design of lifestyle studies in PD, and suggests a more coordinated international effort is required, including ongoing longitudinal observational studies. In combination with pharmaceutical treatments, healthy lifestyle behaviors may slow the progression of PD, empower patients, and reduce disease burden. For optimal care of people with PD, it is important to close this gap in current knowledge and discover whether such associations exist. Introduction Parkinson's disease (PD) is an age-related complex progressive neurodegenerative disorder, with key p...
Source: Frontiers in Neurology - April 29, 2019 Category: Neurology Source Type: research

9 Ways to Squeeze in More Steps Every Day
Every day for the past decade, I’ve tried to dethrone the family walking champ: my 67-year-old dad. Despite my youthful advantage—he has more than 30 years on me, as he’s quick to point out—I haven’t logged more steps than him once. I find this to be both mortifying and a point of vicarious pride; his fitness is remarkable. It’s also excellent motivation to find creative ways to finally out-walk him. My dad and I compete using our favorite pedometer app, which displays each day’s steps in a bar graph. (While we both wear Apple Watches, we like the app best for logging the entire da...
Source: TIME: Health - January 12, 2023 Category: Consumer Health News Authors: Angela Haupt Tags: Uncategorized Exercise & Fitness healthscienceclimate Source Type: news